More than half of the patients with newly diagnosed T2D responded well to Continuous Subcutaneous Insulin Infusion (CSII) therapy in terms of improvements in β-cell function and glycemic control for 1 year after cessation of therapy10. This evidence concerns the gene INS and type 2 diabetes mellitus.